The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Model-based Drug Development
Abstract
The low productivity and escalating costs of drug development have been well documented over the past several years. Less than 10% of new compounds that enter clinical trials ultimately make it to the market, and many more fail in the preclinical stages of development. These challenges in the "critical path" of drug development are discussed in a 2004 publication by the US Food and Drug Administration. The document emphasizes new tools and various opportunities to improve drug development. One of the opportunities recommended is the application of "model-based drug development (MBDD)." This paper discusses what constitutes the key elements of MBDD and how these elements should fit together to inform drug development strategy and decision-making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Ferrari, M. D., Roon, K. I., Lipton, R. B., & Goadsby, P. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06711-3 · Cited by 987
Learning versus confirming in clinical drug development*
Sheiner, L. B. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90160-0 · Cited by 633
Ferrari, M., Goadsby, P., Roon, K., & Lipton, R. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00404.x · Cited by 605
Krams, M., Lees, K. R., Hacke, W., Grieve, A. P., Orgogozo, J.-M., & Ford, G. A. (2003) · Stroke · doi:10.1161/01.str.0000092527.33910.89 · Cited by 430
Pharmacokinetic/Pharmacodynamic Modeling in Drug Development
Sheiner, L. B., & Steimer, J.-L. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.67 · Cited by 351
Holford, N. H. G., Kimko, H. C., Monteleone, J. P. R., & Peck, C. C. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.209 · Cited by 289
Peck, C. C., Barr, W. H., Benet, L. Z., Collins, J., Desjardins, R. E., Furst, D. E., Harter, J. G., Levy, G., Ludden, T., Rodman, J. H., et al. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.47 · Cited by 191
Drug Treatment Effects on Disease Progression
Chan, P., & Holford, N. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.625 · Cited by 160
How Modeling and Simulation Have Enhanced Decision Making in New Drug Development
Miller, R., Ewy, W., Corrigan, B., Ouellet, D., Hermann, D. J., Kowalski, K. G., LOCKWOOD, P. A., Koup, J. R., Donevan, S. D., El‐Kattan, A. F., et al. (2005) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-005-0074-7 · Cited by 150
Self-citationBhattaram, V. A., Booth, B. P., Ramchandani, R. P., Beasley, B. N., Wang, Y., Tandon, V., Duan, J. Z., Baweja, R. K., Marroum, P. J., Uppoor, R. S., et al. (2005) · The AAPS Journal · doi:10.1208/aapsj070351 · Cited by 147
Reigner, B. G., Williams, P. E. O., Patel, I. H., Steimer, J., Peck, C. C., & van Brummelen, P. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733020-00005 · Cited by 121
Model-Based Drug Development: The Road to Quantitative Pharmacology
Zhang, L., Sinha, V. P., Forgue, S. T., Callies, S., Ni, L., Peck, R., & Allerheiligen, S. R. B. (2006) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-006-9010-8 · Cited by 110
Holford, N. H. G., & Peace, K. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.23.11471 · Cited by 92
Model-based development of gemcabene, a new lipid-altering agent
Mandema, J. W., Hermann, D. J., Wang, W., Sheiner, T., Milad, M. A., Bakker-Arkema, R. G., & Hartman, D. (2005) · The AAPS Journal · doi:10.1208/aapsj070352 · Cited by 74
LOCKWOOD, P. A., Ewy, W., Hermann, D. J., & Holford, N. H. G. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9048-8 · Cited by 53
Self-citationMarshall, S. F., Macintyre, F., James, I., Krams, M., & Jonsson, E. N. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645020-00004 · Cited by 32
Self-citationA Bayesian Design and Analysis for Dose-Response Using Informative Prior Information
Smith, M. K., & Marshall, S. F. (2006) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400600860535 · Cited by 20
Self-citation
Cited by
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development
Mould, D., & Upton, R. (2012) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.4 · Cited by 544
The Simcyp ® Population-based ADME Simulator
Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., & Rostami-Hodjegan, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802691074 · Cited by 533
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Morgan, P., Brown, D. G., Lennard, S., Anderton, M. J., Barrett, J. C., Eriksson, U., Fidock, M., Hamrén, B., Johnson, A., March, R. E., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.244 · Cited by 452
Workgroup, E. M., Marshall, S., Burghaus, R., Cosson, V, Cheung, S., Chenel, M., DellaPasqua, O., Frey, N., Hamrén, B., Harnisch, L., et al. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12049 · Cited by 373
Self-citation
Metadata
- Authors
- Lalonde, R. L., Kowalski, K. G., Hutmacher, M. M., Ewy, W., Nichols, D. J., Milligan, P. A., Corrigan, B. W., Lockwood, P. A., Marshall, S. A., Benincosa, L. J., Tensfeldt, T. G., Parivar, K., Amantea, M., Glue, P., Koide, H., & Miller, R.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-05-23
- Volume
- 82
- Issue
- 1
- Pages
- 21-32
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1975404751
- Cited by
- 452
- References
- 21
- FWCI
- 27.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.